retatrutide triple agonist obesity phase 2 trial Eli Lilly's 3 clinical studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments retatrutide triple agonist phase 2

Wegovy has a retail price of around $1,350 for a four-week supply.[3] Insurance coverage varies widely, and many insurance plans do not cover medications for obesity.[4] Supply shortages have also affected access to GLP-1 medications

Inflammation First: How GLP-1s Act Independently of Weight Loss A groundbreaking finding in GLP-1 clinical trials is that these compounds can significantly reduce inflammatory markers and improve inflammatory conditions before any substantial changes in body weight or blood glucose levels are observed

Tirzepatide and hair loss Tirzepatide provides the most directly comparable data because it was the first dual-agonist to track hair loss in pivotal trials

Phase 3: Taper or Stop (Weeks 9+) At week 810, evaluate: is the injury improving

GLP-1 patients generally retain more subcutaneous fat and have fewer nutritional deficiencies

Int J Mol Sci 22(5):2596